Caption Management’s Aldeyra Therapeutics ALDX Stock Holding History

Caption Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-190,000	Closed	-$846K	–	1404
2022 Q1	$846K	Sell	190,000 -449,700	-70%	-$1.79M	0.01%	1025
2021 Q4	$2.56M	Sell	639,700 -85,100	-12%	-$649K	0.03%	700
2021 Q3	$6.36M	Buy	724,800 +604,800	+504%	+$5.55M	0.07%	362
2021 Q2	$1.36M	Buy	120,000 +101,500	+549%	+$1.22M	0.02%	806
2021 Q1	$219K	Buy	+18,500	New	+$213K	﹤0.01%	905
2019 Q2	–	Sell	-54,000	Closed	-$487K	–	644
2019 Q1	$487K	Buy	+54,000	New	+$459K	0.03%	441
2018 Q4	–	Sell	-25,000	Closed	-$345K	–	455
2018 Q3	$345K	Buy	+25,000	New	+$203K	0.02%	435

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Caption Management's ALDX Position: Q2 2026 in Review

Caption Management held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 165,000 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1389.

Caption Management first reported a position in ALDX in Q3 2021 and has held it in 8 quarters since. The position peaked at $1.98M in Q4 2024. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Caption Management held 165,000 shares of Aldeyra Therapeutics worth $351K as of Q2 2026.
Caption Management left its Aldeyra Therapeutics share count unchanged in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1389 holding.
Caption Management first reported a position in Aldeyra Therapeutics in Q3 2021 and has held it in 8 quarters since.
Caption Management's Aldeyra Therapeutics position peaked at $1.98M in Q4 2024.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.